American Cancer Society Updates Cervical cancer Screening guidelines with Self-Collection Option
December 6,2025 - In a significant shift to broaden access and improve participation rates,the American Cancer Society (ACS) has updated its cervical cancer screening guidelines to include at-home self-collection for human papillomavirus (HPV) testing.The revised recommendations, published today, offer an option to customary pelvic exams for HPV screening, perhaps reaching individuals who face barriers to conventional screening methods.
This update addresses longstanding disparities in cervical cancer prevention, particularly among those who are under-screened or have limited access to healthcare. Cervical cancer is largely preventable through regular screening, but factors like geographic location, financial constraints, fear of discomfort, and cultural sensitivities can hinder participation. The inclusion of self-collection aims to overcome these obstacles, offering a more convenient and private option for individuals aged 25 to 65.
The updated guidelines reflect growing evidence supporting the efficacy of self-collected HPV tests. A pivotal study, SELF-CERV (NCT06120205), is currently underway to further evaluate the effectiveness of self-collection. The Food and Drug Administration (FDA) previously approved the Teal Wand, the first at-home self-collection device for cervical cancer screening, in April 2024, paving the way for broader implementation of this approach.
The ACS continues to recommend primary HPV testing as the preferred method for cervical cancer screening,with options for co-testing (HPV and Pap test) also remaining viable. Individuals should discuss the most appropriate screening strategy with their healthcare provider, considering their individual risk factors and preferences. The updated guidelines are intended to empower individuals to take control of their health and ensure more equitable access to life-saving cervical cancer prevention.
